MedTrace Logo

Prescription Drug Safety and Effectiveness in Multiple Sclerosis

NCT04472975 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35000

Last updated 2024-05-16

No results posted yet for this study

Summary

The goal of our research is to find out how safe and effective the drugs used to treat multiple sclerosis (MS) are when used in the everyday, real world. To achieve these study goals, we have two main study Themes. The first Theme focuses on how effective the MS drugs are. We will examine whether the MS drugs can extend life expectancy or prolong a person's ability to stay mobile and walk. We will also look at whether the MS drugs have a beneficial effect on reducing the number of times a person with MS is admitted to a hospital or visits a physician. The second Theme focuses on side effects, including whether the MS drugs are associated with harmful effects, such as cancer, stroke or depression. We will be able to compare the different MS drugs to each other. Also, we will see if men and women or people of different ages and with other illnesses (such as having both MS and diabetes) respond to the MS drugs differently. Our findings will help people with MS and their physicians when trying to make decisions as to which MS drug might be best for them.

Conditions

Interventions

DRUG

Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS

Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.

Sponsors & Collaborators

  • University of Manitoba

    collaborator OTHER

  • Dalhousie University

    collaborator OTHER

  • University of Saskatchewan

    collaborator OTHER

  • Alberta Health services

    collaborator OTHER

  • University of Alberta

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Helen Tremlett, PhD · University of British Columbia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1996-01-01
Primary Completion
2018-03-31
Completion
2018-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04472975 on ClinicalTrials.gov